Monday
07.22.2019
10:14 PM
Login form
Search
Calendar
Entries archive

My site

Main » 2019 » May » 21

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week

 

•    Exploratory data showed a greater proportion of patients receiving vedolizumab achieved clinical response at week 14 than adalimumab

•    Additional exploratory data on absence of active histologic disease showed vedolizumab was associated with a greater reduction of microscopic inflammation in the gut compared to adalimumab

•    Results provide additional information to the recent presentation of primary endpoint data from the VARSITY study, which demonstrated superiority of vedolizumab to adalimumab in achieving clinical remission at week 52

OSAKA, Japan-Monday 20 May 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited ( ... Read more »

Views: 9 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

Mr. Yasseen will use his experience and expertise to introduce Pennington Fund to South Africa

HONG KONG-Thursday 16 May 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Mr. Yasseen is a financial investment professional with more than 12 years of experience in South Africa. Pennington specializes in offering tax-efficient Asian offshore investment opportunities to international clients. Yusuf Yasseen and Pennington Fund will now introduce that same offshore experience to South African HNW, institutional investors and advisors.

Learn more about Yusuf: https://www.linkedin.com/in/therealyusufyasseen/

About Pennington:

Pennington is an Asian registered private non-ETF hedge fund that serves the complex and comprehensive financial needs of high net worth and institutional investors. Founded in 1998, Pennington is led by professionals with extensive experience managing diverse investment opportunities. Pennington serves successful investors by providing obj ... Read more »

Views: 8 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

SAN FRANCISCO-Monday 20 May 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- GLIDE is pleased to announce the annual eBay for Charity Auction for Power Lunch with Warren Buffett, which will begin at 7:30 pm PDT on Sunday, May 26 and end at 7:30 pm PDT on Friday, May 31, 2019. This year marks the 20th anniversary of the legendary auction, which to date has provided nearly $30 million to support GLIDE’s comprehensive suite of social services that help San Francisco’s most vulnerable residents overcome hunger, poverty, homelessness and health challenges as well as social isolation and marginalization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005017/en/

“It makes a difference, and it translates into human beings finding that there is hope in life and that something better is there,” Mr. Buffett said recently about the money raised for GLIDE over the past 20 years.

The a ... Read more »

Views: 8 | Added by: africanewsline | Date: 05.21.2019 | Comments (0)

• Million-patient study reveals gaps in long-term therapy adherence among various sub-populations

• Study helps sleep specialists identify which populations generally need more clinical support

 

DALLAS-Monday 20 May 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference.

The study found significant differences in one-year adherence between people of different ages and disease severity levels:

    Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women.
    People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%).
    People with self-repo ... Read more »

Views: 8 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

Company support teams and individuals recognized for outstanding customer support and service innovation

LAS VEGAS-Friday 17 May 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced it has been honored with seven Stevie® Awards for Sales & Customer Service for the Company’s unwavering commitment to providing outstanding client service to organizations around the world. Rimini Street received a gold award for the Innovation in Customer Service category and also received awards for Front-Line Customer Service Professional of the Year, Customer Service Department of the Year, Woman of the Year in Customer Service, and Back-Office Customer Service Team of the Year.

Awards Reflect Company Commitment to Service and Client Success

Rimini Stree ... Read more »

Views: 8 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

New Research & Development Lab Demonstrates Strong Commitment to Continuous Innovation

WILMINGTON, Del. -Thursday 16 May 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- The LYCRA Company, a leading provider of fiber and technology solutions for the global apparel and personal care industries, announced today it will officially open its new Advanced Textile Innovation Center (ATIC) in Nanhai, China on May 16. The new 4,500-square-meter Research & Development (R&D) laboratory, which is the company’s fourth, represents a significant increase in the U.S.-based firm’s global R&D capabilities.

Scientists at the R&D center will help mills, brands and retailers throughout Asia, as well as Western-based companies with local sourcing offices, create innovative fabrics and garments using The LYCRA Company’s branded textile solutions, which include LYCRA® fiber, LYCRA HyFit® fiber, COOLMAX® fiber and THERMOLITE® fiber. The rese ... Read more »

Views: 8 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

INGELHEIM, Germany -Monday 20 May 2019 [ AETOS Wire ]

Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USA
Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3
FDA grants priority review to application for regulatory approval for nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD)
(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show that nintedanib slows the loss of pulmonary function in patient ... Read more »

Views: 7 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

New Reach and Frequency Capabilities Help Advertisers Reach “Light TV Viewing” Audiences Who Watch Linear TV Infrequently

Xandr’s Cross-Screen Addressable Solution Now Uses the Power of Community

Addressable Inventory Now Includes Set-Top Box VOD and Live Linear from More Than 80 TV Networks

NEW YORK-Thursday 16 May 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Xandr, AT&T’s advanced advertising and analytics company, has enhanced its addressable TV solutions to include new reach and frequency capabilities, expanded cross-screen addressability, and enabled broader access to video on-demand inventory. The enhancements to Xandr’s addressable TV capabilities provide the perfect complement to media buyers who need better control over their TV buys during this Upfront season.

 “Xandr is the leader in advanced TV advertising* - not only as a trusted partner to brands, but also as a provider for our powerful and ... Read more »

Views: 5 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

– New Data to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and the Congress of the European Hematology Association (EHA) Demonstrate Advancements in Medicines Designed to Address the Unmet Needs of Patients for a Variety of Cancers –

– Eight Takeda-Sponsored Abstracts Accepted for Presentation at ASCO 2019 and 11 Abstracts Accepted for Presentation at EHA 2019 – 

CAMBRIDGE, Mass. & OSAKA, Japan-Monday 20 May 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam.

“We look forward to presenting data at ASCO and EHA that illustrate the continued progress of our portfolio in both clinical researc ... Read more »

Views: 8 | Added by: africa-live | Date: 05.21.2019 | Comments (0)

More than $150 billion in sales predicted over the next five years

LONDON-Thursday 16 May 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Jetcraft, the global leader in business aircraft sales and acquisitions, is releasing a 5-Year New & Pre-Owned Business Aviation Market Forecast – the first of its kind to predict both new and pre-owned aircraft transactions.

The new forecast anticipates 11,765 pre-owned transactions over the next five years, equating to $61bn in value, and 3,444 new deliveries, representing $90.5bn. By 2023 it is expected that industry value will reach nearly $30bn per annum.

Jahid Fazal-Karim, Owner and Chairman of the Board at Jetcraft, says: “This is the first forecast to precisely analyze both new and pre-owned business aircraft transactions over a five-year period. The findings show that our industry will continue to grow in size and scale, hitting nearly $30bn per year in revenue by 2023, a truly impressive figure.

... Read more »
Views: 7 | Added by: africa-live | Date: 05.21.2019 | Comments (0)